<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">systhiper-712</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group></article-categories><title-group><article-title>Антигипертензивная эффективность ирбесартана</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Остроумова</surname><given-names>О. Д.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щукина</surname><given-names>Г. Н.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомина</surname><given-names>В. М.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ГБОУ ВПО Московский государственный медико-стоматологический университет</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>09</day><month>02</month><year>2023</year></pub-date><volume>8</volume><issue>4</issue><fpage>16</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Остроумова О.Д., Щукина Г.Н., Фомина В.М., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Остроумова О.Д., Щукина Г.Н., Фомина В.М.</copyright-holder><copyright-holder xml:lang="en">Остроумова О.Д., Щукина Г.Н., Фомина В.М.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/712">https://www.syst-hypertension.ru/jour/article/view/712</self-uri></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Клиническая фармакология. Под ред. В.Г.Кукеса. Изд. 4, М.: ГЭОТАР-Медиа, 2008; с. 392-5.</mixed-citation><mixed-citation xml:lang="en">Клиническая фармакология. Под ред. В.Г.Кукеса. Изд. 4, М.: ГЭОТАР-Медиа, 2008; с. 392-5.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Диагностика и лечение артериальной гипертензии. Российские рекомендации, 4-я редакция. Системные гипертензии 2010; 3: 5-26.</mixed-citation><mixed-citation xml:lang="en">Диагностика и лечение артериальной гипертензии. Российские рекомендации, 4-я редакция. Системные гипертензии 2010; 3: 5-26.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fogari R, Ambrosoli S, Corradi L et al. Irbesartan Multicenter Investigator's Group. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15 (12-1): 1511-8.</mixed-citation><mixed-citation xml:lang="en">Fogari R, Ambrosoli S, Corradi L et al. Irbesartan Multicenter Investigator's Group. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15 (12-1): 1511-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kassler-Taub K, Littlejohn T, Elliot W и др. Irbesartan. Losartan Study Investigators. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild-to-Moderate Hypertension. Am J Hypertens 1998; 11 (4-1): 445-53.</mixed-citation><mixed-citation xml:lang="en">Kassler-Taub K, Littlejohn T, Elliot W и др. Irbesartan. Losartan Study Investigators. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild-to-Moderate Hypertension. Am J Hypertens 1998; 11 (4-1): 445-53.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Oparil S, Guthrie R, Lewin AJ и др. Irbesartan. Losasartan Study Investigators. Clin Ther 1998; 20 (3): 398-409.</mixed-citation><mixed-citation xml:lang="en">Oparil S, Guthrie R, Lewin AJ и др. Irbesartan. Losasartan Study Investigators. Clin Ther 1998; 20 (3): 398-409.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Korlipara K, van Possum P et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7 (2): 135-342.</mixed-citation><mixed-citation xml:lang="en">Mancia G, Korlipara K, van Possum P et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7 (2): 135-342.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mimran A, Ruilope L, Kerwin L et al. A rindomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12 (3): 203-8.</mixed-citation><mixed-citation xml:lang="en">Mimran A, Ruilope L, Kerwin L et al. A rindomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12 (3): 203-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Larochelle P, Flack JM, Marbury TC и др. Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80 (12): 1613-5.</mixed-citation><mixed-citation xml:lang="en">Larochelle P, Flack JM, Marbury TC и др. Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80 (12): 1613-5.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Stumpe KO, Haworth D, Hoglund C et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan with Atenolol for Treatment of Hypertension. Blood Press 1998; 7 (1): 31-7.</mixed-citation><mixed-citation xml:lang="en">Stumpe KO, Haworth D, Hoglund C et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan with Atenolol for Treatment of Hypertension. Blood Press 1998; 7 (1): 31-7.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М., Медиа Медика. 2007; 183 с.</mixed-citation><mixed-citation xml:lang="en">Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М., Медиа Медика. 2007; 183 с.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
